

LymphoTrack[®] Assays

NGS Study of Hematology-Oncology
Clonality Testing


Molecular testing of clonality

Current methods are effective, but limited

- Low throughput
- Low sensitivity
- Difficult to interpret
- Cannot readily differentiate between clonal populations that have the same PCR product
- Not appropriate for MRD research


There is a need for improvement

The Next Step in Clonality Assessment



Fragment Analysis

- **Reduced testing time**
(1-2 days)
- **Base pair resolution**
Sequences obtained by cloning & Sanger sequencing
- **Custom assay required to track clones (MRD)**
- **Widely used method**
many references available
- **Can be hard to interpret and is subjective**



NGS

- **Increased objectivity**
specific sequence provided
- **Reduced false positives**
non-specific bands filtered
- **Increased sensitivity**
- **Same reagents & workflow**
for the study of clonality, SHM, & MRD
- **Less analysis time required**


Advantages of NGS testing

- Determines the **DNA sequence** of clonal rearrangements

- Increases **objectivity**

- Identifies the **full range** of clonal populations in a specimen

- Allows for **clonality** confirmation in a single assay



- Allows **tracking** of clonal populations with the **same reagents** and **workflow**



A molecular analysis revolution

- **Next Generation Sequencing**

- Sequence millions of nucleic acid strands simultaneously
- Very sensitive
- High degree of multiplexing – look at many targets simultaneously

- **Impressive data analysis requirements**

- Has rapidly increased the field of bioinformatics
- Is typically highly complex


- Has touched all areas of life and medical sciences and changed how we understand the world

Vocabulary

- **Adapters** – short nucleotide sequences
 - Allow amplicons to bind to sequencing component (bead of flow cell)
 - Use to amplify adapter-ligated DNA fragments only
- **Indexes/Indices**
 - Each DNA fragment in a sample is ‘tagged’ with a short sequence specific to that sample
 - Indexes/Indices are used after sequencing to separate fragments into different samples
- **Library**
 - Collection of amplicons with indexed adapters
 - Can be ‘pooled’ with other libraries for multiplex sequencing

NGS Workflow

“Typical” workflow



“An introduction to Next-Generation Sequencing Technology”, Illumina[®], https://www.illumina.com/content/dam/illumina-marketing/documents/products/illumina_sequencing_introduction.pdf (Accessed July 2020)

Available Assays & Software



B-Cell

- *IGHV* Leader SHM*
- *IGH* FR1/2/3 Combo
- *IGH* FR1
- *IGH* FR2
- *IGH* FR3
- *IGK*

T-Cell

- *TRG*
- *TRB**

Software


- LymphoTrack[®] Software
- MRD Software - Research Use Only (RUO)

*MiSeq Only




- **One-Step PCR** Master Mixes
- **Multiplexing** – Reduces Costs by Combining:
 - Multiple Samples - up to 12 (Ion S5/PGM[™]) & 24 (MiSeq[®])
 - Multiple Invivoscribe Assays - up to 72 or 168 Samples
 - Other Platform-Specific Assays
- **Unparalleled Sensitivity**
 - Unparalleled clonality detection with the ability to identify and track the specific sequence of clonal populations for MRD research studies.
- **Analysis Software Package - Included**

LymphoTrack® Workflow

Easy Workflow



Comprehensive menu

Available Sequencing Platforms	 MiSeq[®]	 Ion S5[™]	 Ion PGM[™]
Menu	<p>B-Cell <i>IGHV (Leader)</i> <i>IGH FR1</i> <i>IGH FR2</i> <i>IGH FR3</i> <i>IGK</i></p> <p>T-Cell <i>TRG</i> <i>TRB</i></p>	<p>B-Cell <i>IGH FR1</i> <i>IGH FR2</i> <i>IGH FR3</i> <i>IGK</i></p> <p>T-Cell <i>TRG</i></p>	<p>B-Cell <i>IGH FR1</i> <i>IGH FR2</i> <i>IGH FR3</i> <i>IGK</i></p> <p>T-Cell <i>TRG</i></p>
Kit size(s)	8-index or 24-index kits	12 barcodes	12 barcodes
Validated Sequencing Kits	V2 (2 x 150 bp) V2 (2 x 250 bp) V3 (2 x 300 bp)	Ion 520 [™] Ion 530 [™]	Ion 316 [™] v2 BC Ion 318 [™] v2 BC

Included in the LymphoTrack® Kits

Library preparation and analysis


- Kit contents
 - 1 **mastermix** per index/barcode
 - Required **controls**
 - LymphoTrack® analysis **software**
- Kit sizes:

Platform	Kit Type	# of indices/ barcodes	Reactions per mastermix	Reactions per kit
MiSeq®	Kit A	8	5	40
	Panel	24	5	120
	Panel B	24	5	120
S5/PGM™	All	12	5	60

*Only available for IGH FR1

Local, offline and easy to use

- Included with each LymphoTrack[®] kit
- Available for both Ion S5/PGM[™] and Illumina[®] MiSeq[®] platforms
- Does not require bioinformatics personnel
- Can run on most standard windows platforms
- Utilizes FASTQ files
- Fast results reported in individual PDF reports or in Excel



Summary of Sequencing Workflows

Summary of LymphoTrack* Assays – S5/PGM




	IGH FR1	IGH FR2	IGH FR3	IGK	TRG
Average Target Size (bp)	295	243	103	222	147
Average Amplicon Size Including Target, Index, and Adaptors (bp)	430	370	240	390	280
DNA Input (ng/PCR)	50				
Validated PCR Cycles	29				
Purification Method	AMPure XP Beads (1.8:1 ratio)				
Quantification Method	Agilent 2100 Bioanalyzer or Perkin Elmer LabChip [®] GX				
Planned Run Setting for Flows**	850			500 or 850	
Recommended Sequencing Kit**	<p>For Ion S5™ use: Ion 520™ & Ion 530™ Kit – OT2 or Ion 510™ & 520™ & Ion 530™ Kit – Chef</p> <p>For Ion PGM™ use: Ion PGM™ Hi-Q™ View OT2 Kit & Ion PGM™ Hi-Q™ View Sequencing Kit & Ion PGM™ Wash 2 Bottle Kit</p>				

Summary of Sequencing Workflows

Summary of LymphoTrack* Assays - Miseq

	IGHV Leader SHM	IGH FR1	IGH FR2	IGH FR3	IGK	TRG	TRB
Target Size (bp)	483	295	243	104	222	147	290
Amplicon Size Including Target, Index, and Adaptors (bp)	660	450	390	260	410	300	400
DNA Input (ng/PCR)	50						
Validated PCR Cycles	32	29					
Purification Method	AMPure XP Beads (1:1 ratio)						AMPure XP Beads (0.7:1 ratio)
Quantification Method	KAPA qPCR						
Sample Sheet Settings**	Cycles Read1: 301 Cycles Read2: 301	Cycles Read1: 251 Cycles Read2: 251		Cycles Read1: 151 Cycles Read2: 151	Cycles Read1: 251 Cycles Read2: 251	Cycles Read1: 151 Cycles Read2: 151	Cycles Read1: 251 Cycles Read2: 251
Recommended Sequencing Kit**	MiSeq v3 Reagent (600-cycle)	MiSeq v2 Reagent (500-cycle) or MiSeq v3 Reagent (600-cycle)		MiSeq v2 Reagent (300-cycle) or MiSeq v2 Reagent (500-cycle) or MiSeq v3 Reagent (600-cycle)	MiSeq v2 Reagent (500-cycle) or MiSeq v3 Reagent (600-cycle)	MiSeq v2 Reagent (300-cycle) or MiSeq v2 Reagent (500-cycle) or MiSeq v3 Reagent (600-cycle)	MiSeq v2 Reagent (500-cycle) or MiSeq v3 Reagent (600-cycle)

Sequencing Instruments


Available Sequencing Platforms	 MiSeq[®]	 Ion S5[™]	 Ion PGM[™]
Run Time	36-56 Hours	6-17.5 Hours	5-8 Hours
Reads Per Run	15 million (V2 standard) 25 million (V3)	3-5 million (Ion 520 chip) 15-20 million (Ion 530 chip)	2-3 million (316 chip) 4-5.5 million (318 chip)
Read Lengths	V2 (2 x 150 bp) V2 (2 x 250 bp) V3 (2 x 300 bp)	Ion 520 [™] (400 bp) Ion 530 [™] (400 bp)	Ion 316 [™] v2 BC (400 bp) Ion 318 [™] v2 BC (400 bp)

Key Factors

- How many samples?
- How many targets?
- Which targets?

These will determine:

- # of indices/barcodes needed
- MiSeq[®] or Ion Torrent[™] chemistry
- Cost per target and per sample



Increasing Capture Rate

Easy to combine:

- IGH and IGK
- TRB and TRG

Advantages of Combining Targets:

- Highest capture rate
- Higher confidence

B-Cell Targets

	IGH (FR1, 2 & 3)	IGK (Vk - Jk & Kde)	IGH+IGK
MCL(%)	100	100	100
B-CLL/SLL(%)	100	100	100
FL(%)	84	84	100
MZL(%)	87	83	97
DLBCL(%)	79	80	96
Total(%)	88	88	98

PAS Evans et al., Leukemia. 2006 21:201-206.

T-Cell Targets

	TRB	TRG	TRB+TRG
T-PLL(%)	100	94	100
T-LGL(%)	96	96	100
PTCL-U(%)	98	94	100
AITL(%)	89	92	95
ALCL(%)	74	74	79*
Total(%)	91	89	94 (99)*


J.J.M. van Krieken et al. Leukemia. 2007 21:201-206.

Testing Complementary Gene Targets in Parallel Improves Confidence!

*Approximately 20–25% of ALCL are known to have no TCR gene rearrangements and are defined as null ALCL; J.J.M. van Krieken et al. *Leukemia*. 2007 21:201-206.

Increasing Detection Rate

Example of how using multiple targets can increase the detection rate in clonality in multiple myeloma samples



"Comparison of LymphoTrack[®] Assays - MiSeq[®] and Flow Cytometry for Clonality and Minimum Residual Disease Assessment in Multiple Myeloma", InvivoScribe, EHA Meeting 2018

Multiplexing

Platform	Sequencing Kit	LymphoTrack [®] Kits	Number of Targets
Illumina [®] MiSeq [®]	V2 (2 x 150 bp)	FR3 and TRG	Up to 2 targets
	V2 (2 x 250 bp)	FR1, FR2, FR3, IGK, TRB and TRG	Up to 4 targets*
	V3 (2 x 300 bp)	IGHV, FR1, FR2, FR3, IGK, TRB and TRG	Up to 7 targets
Ion S5 [™] and Ion PGM [™]	Ion 520	FR1, FR2, FR3, IGK and TRG	Up to 5 targets
	Ion 530	FR1, FR2, FR3, IGK and TRG	Up to 5 targets
	Ion 316	FR1, FR2, FR3, IGK and TRG	Up to 3 targets
	Ion 318	FR1, FR2, FR3, IGK and TRG	Up to 5 targets

* Due to capacity of the V2 Sequencing Kit it is possible to sequence only up to 4 targets.

- 1 Determine the Targets to be tested & necessary Sequencing Kit**
 - **Multiple Targets** can be multiplexed from any LymphoTrack[®] B- and T-cell kit
 - Select the MiSeq[®] or S5/PGM[™] Sequencing kit compatible with the **largest amplicon** in the multiplex
- 2 Calculate the # of Reads available per Sample**
$$\frac{\begin{array}{l} = \text{ # Total reads available} \\ \div \text{ # Samples} \\ \div \text{ # Targets per sample} \end{array}}{\text{ # Reads per Target, Per Sample}}$$
- 3 Compare with the minimum # of Reads desired**
 - # of Reads per Target

- 4 **Assign one Index per Sample**
 - Assign the **same index per Sample across different Targets**
 - e.g. Sample A - Index 01 for *IGH FR1*, Index 01 for *TRG*, etc.
 - e.g. Sample B - Index 02 for *IGH FR1*, Index 02 for *TRG*, etc.
 - A **unique index** should also be assigned to the **Positive and Negative Controls**
 - e.g. Positive Control - Index 08 for *IGH FR1*, Index 08 for *TRG*, etc.
 - e.g. Negative Control - Index 09 for *IGH FR1*, Index 09 for *TRG*, etc.
 - **NTC** does not need to be sequenced so **any index can be used**
 - e.g. NTC – Index 08 for *IGH FR1*, Index 08 for *TRG*, etc.

Multiplexing Example

- Determine the Targets to be tested & necessary Sequencing Kit**
 - Targets:** We will multiplex *IGH* Leader, *IGH* FR1, FR2, FR3, *IGK*, *TRG* and *TRB*
 - Select **Sequencing kit:** *IGH* Leader is the largest target and requires as minimum a MiSeq[®] v3 Flow Cell (25 Million reads available).

- Calculate the # of Reads available per Sample**

$$\begin{aligned} &= \# \text{ Total reads available} \\ &\div \# \text{ Samples} \\ &\div \# \text{ Targets per sample} \end{aligned}$$

Reads per Target, Per Sample

$$\begin{aligned} &20,000,000 \text{ Reads}^* \\ &\div 24 \text{ Samples} \\ &\div 7 \text{ Targets} \end{aligned}$$

~119,000 Reads per Target,
per Sample

- Compare with the minimum # of Reads desired**

- # of Reads per Target



* Only 80% of 25 Million reads are considered = 20 Million reads as loading might not be perfect

Multiplexing Example

4

Assign one Index per Sample

- Assign the **same index per Sample across different Targets**
- A **unique index** should also be assigned to the **Positive and Negative Controls**
- **NTC** does not need to be sequenced so **any index can be used**

Index	IGH FR1	TRG	Target X ...
1	Index 01 Sample A	Index 01 Sample A	Index 01 Sample A
2	Index 02 Sample B	Index 02 Sample B	Index 02 Sample B
3	Index 03 Sample C	Index 03 Sample C	Index 03 Sample C
4	Index 04 PosCtrl	Index 04 PosCtrl	Index 04 PosCtrl
5	Index 05 NegCtrl	Index 05 NegCtrl	Index 05 NegCtrl
6	Index 05 NTC	Index 05 NTC	Index 05 NTC
...

Multiplexing - Summary

Easily maximize run efficiency

- Use same index/barcode across **multiple targets**
- The LymphoTrack[®] software can assign all reads to the correct target
- MiSeq[®] example

Index	IGHV	FR1	FR2	FR3	IGK	TRG	TRB
1	NC	NC	NC	NC	NC	NC	NC
2	PC	PC	PC	PC	PC	PC	PC
3	SHM PC	Sample 1	Sample 1	Sample 1	Sample 1	Sample 2	Sample 2
4	Sample 3	Sample 4	Sample 4	Sample 4	Sample 4	Sample 5	Sample 5

↓
Up to 24
indices

- Possible to generate up to 153 sample results in one run (v3 flow cell)

The following NGS instruments are suitable for LymphoTrack[®] except,

1. Illumina[®] MiSeq[®]

2. Ion PGM[™]

3. Illumina[®] NextSeq[®]

4. Ion S5[™]

5. Illumina[®] MiniSeq[™]

Somatic hypermutation analysis can be done using the Ion Torrent™ platform?

1. Yes, using *FR1*
2. Yes, using *IGK*
3. No

Which kits can be analyzed on the Illumina[®] MiSeq[®] using the v2 (2x250) flow cell?

1. *TRB* and *TRG*
2. *FR1*, *FR2*, *FR3*, and *IGK*
3. *FR3* and *TRG*
4. *FR1*, *FR2*, *FR3*, *IGK*, *TRG* and *TRB*

Which of the following flow cells has not been validated for the Illumina[®] MiSeq[®] instrument by Invivoscribe?

1. V3, 2x300 bp
2. V2, 2x250 bp
3. V2, 2x150 bp
4. V2 nano, 2x250 bp

Which library quantitation methods are validated for the LymphoTrack[®] MiSeq[®] kits?

1. Bioanalyzer

2. Kapa qPCR kits

3. Qubit


4. Tape station

LymphoTrack[®] Software

Data analysis and Interpretation




Analysis Workflow



- Computer requirements

- **64 bit** Windows, 4GB RAM (or more), Intel Core Duo 2 or newer CPU
- Java 8 (**64 bit**) or newer
- PDF reader
- CD-ROM drive to access the program on supplied CD

Analyze Data in Just 4 Steps



1. Select target(s) analyzed

2. Choose decimal mark

3. Browse for data folder

4. Begin automated analysis

Data Output – PDF Report

Merged Read Summary

- All sequences that differ by only 1 or 2 bp are merged
 - Accounts for library prep and sequencing errors
- Shows read count after final analysis
- Full sequence can be copied from PDF report

LymphoTrack Report for assay LEADER
Sample name: Leader_positive_S23_L001_001_combined

Total Read Count: 474947
IndexQ30: 87.88
Caution: Do not edit fields and save.

Top 10 Merged Read Summary


Rank	Sequence	Length	Merge count	V-gene	J-gene	% total reads	Cumulative %	Mutation rate to partial V-gene (%)	In-frame (Y/N)	No Stop codon (Y/N)	V-coverage	CDR3 Seq
1	TTCTCGTGGTGGG	455	50248	IGHV4-59_08	IGHJ4_02	10.58	10.58	11.26	Y	Y	98.63	GCGAGACGGAGC
2	CTGCTACTGACTG	319	192	IGHV2-70_10	IGHJ4_02	0.04	10.62	4.32	n/a	N	35.55	not found
3	CTGCTGCTGACCA	466	175	IGHV2-5_01	IGHJ5_01	0.04	10.66	6.62	Y	Y	100.00	GCACACAGACCG
4	CTGCTGCTGACCA	457	162	IGHV2-5_05	IGHJ6_02	0.03	10.69	2.99	Y	Y	99.67	GCACACAGATACT
5	CTGCTGCTGACCA	474	154	IGHV2-5_05	IGHJ4_02	0.03	10.72	3.99	Y	Y	99.67	GCACACAGATACT
6	CTGCTGCTGACCA	454	150	IGHV2-5_10	IGHJ5_02	0.03	10.76	11.78	Y	Y	98.99	GCATATGGTGTAA
7	CTGCTGCTGACCA	469	139	IGHV2-5_01	IGHJ4_02	0.03	10.78	1.32	Y	Y	97.68	GCACTCGCGACAC
8	CTCGCCCTCCTCC	466	139	IGHV5-51_01	IGHJ4_02	0.03	10.81	7.09	Y	Y	99.32	GCGAGATACTATT
9	CTGCTACTGACTG	490	137	IGHV2-70_10	IGHJ3_02	0.03	10.84	0.66	Y	Y	99.34	GCACGGATTCTCT
10	CTGCTGCTGACCA	478	135	IGHV2-5_10	IGHJ6_02	0.03	10.87	3.70	Y	Y	98.99	GCATACACTTGT

TTCTCTGGGTTCTCACTACCACTAGGGGATTGGGTGTGGCCTGGATCCGTCAGCCCCAGGAAAGGCCCTGGAGTGGCTTGCCTCATTTCCTGGGATGATGATA
AACGCTACAGCCCATCTCTGAAGAGCAGACTCACCATCACCAGGACGCCTCCAAGAACAGGTGGTTCCTTACAATGACCAACATGGACCCTGTAGACACAGCCAC
CTATTACTGTGCACACAGCGGGAGCTACCAAGGTGGGACTACCTATTACCCACACTACTATTTTGACTACTGGGGCCAGGGAAACCCT

Data Output – PDF Report

Sequence Frequency Graph

- Displays rearrangements organized by families
- Based on top 200 sequences
- Solid color bar pieces represent one clonal sequence
- Stacked bars are from the same family, but may or may not be the same clone




Data Output – PDF Report

V-J Usage Graph

- Displays V-gene and J-gene recombinations
- Bar is not based on a particular clone
- Frequency of a pair of families based on amount of reads

V-J Usage: Top 200 Sequences



Data Output – PDF Report

Top 200 Read Summary

- Unmerged read summary of top 200 sequences
- Top sequences may represent same clone and are merged together downstream
- Fewer than 200 reads may be displayed depending on the sample

Top 200 Read Summary

Rank	Sequence	Length	Raw count	V-gene	J-gene	% total reads	Cumulative %	Mutation rate to V-gene (%)	In-frame (Y/N)	No Stop codon (Y/N)	V-coverage	CDR3 seq
1	TTCTCGTGTTGGC+	455	35909	IGHV4-59_08	IGHJ4_02	7.56	7.56	11.26	Y	Y	98.63	GCGAGACGGAGC+
2	TTCTCGTGTTGGC+	455	7484	IGHV4-59_08	IGHJ4_02	1.58	9.14	11.60	Y	Y	98.63	GCGAGACGGAGC+
3	TTCTCGTGTTGGC+	455	911	IGHV4-59_08	IGHJ4_02	0.19	9.33	11.60	Y	Y	98.63	GCGAGACGGAGC+
4	TTCTCGTGTTGGC+	455	395	IGHV4-59_08	IGHJ4_02	0.08	9.41	11.60	Y	Y	98.63	GCGAGACGGAGC+
5	TTCTCGTGTTGGC+	455	386	IGHV4-59_08	IGHJ4_02	0.08	9.49	11.26	Y	Y	98.63	not found
6	TTCTCGTGTTGGC+	455	370	IGHV4-59_08	IGHJ4_02	0.08	9.57	11.26	Y	Y	98.63	not found
7	TTCTCGTGTTGGC+	455	366	IGHV4-59_08	IGHJ4_03	0.08	9.65	11.26	Y	Y	98.63	GCGAGACGGAGC+
8	TTCTCGTGTTGGC+	455	318	IGHV4-59_08	IGHJ4_02	0.07	9.71	11.60	Y	Y	98.63	GCGAGACGGAGC+
9	TTCTCGTGTTGGC+	455	310	IGHV4-59_08	IGHJ4_02	0.07	9.78	11.26	Y	Y	98.63	GCGAGACGGAGC+
10	TTCTCGTGTTGGC+	455	194	IGHV4-59_08	IGHJ4_02	0.04	9.82	11.60	Y	Y	98.63	GCGAGACGGAGC+
11	CTGCTACTGACTG+	319	192	IGHV2-70_10	IGHJ4_02	0.04	9.86	4.32	n/a	N	35.55	not found
12	TTCTCGTGTTGGC+	455	183	IGHV4-	IGHJ4_02	0.04	9.90	11.95	Y	Y	98.63	GCGAGACGGAGC+

Data Output – IGHV

Top 10 Merged Read Summary

- The Read Summary tab only shows the top 10 reads after merging with the top 500 reads that differ in 1 or 2 nucleotides

Note: This analysis is also possible with *IGH FR1*

LymphoTrack Report for assay LEADER

Sample name: Leader_positive_S23_L001_001_combined

Total Read Count: 474947

IndexQ30: 87.88

Caution: Do not edit fields and save.

Top 10 Merged Read Summary

Rank	Sequence	Length	Merge count	V-gene	J-gene	% total reads	Cumulative %	Mutation rate to partial V-gene (%)	In-frame (Y/N)	No Stop codon (Y/N)	V-coverage	CDR3 Seq
1	TTCTCGTGGTGGC	455	50248	IGHV4-59_08	IGHJ4_02	10.58	10.58	11.26	Y	Y	98.63	GCGAGACGGAGC
2	CTGCTACTGACTG	319	192	IGHV2-70_10	IGHJ4_02	0.04	10.62	4.32	n/a	N	35.55	not found
3	CTGCTGCTGACCA	466	175	IGHV2-5_01	IGHJ5_01	0.04	10.66	6.62	Y	Y	100.00	GCACACAGACCGC
4	CTGCTGCTGACCA	457	162	IGHV2-5_05	IGHJ6_02	0.03	10.69	2.99	Y	Y	99.67	GCACACAGATACT
5	CTGCTGCTGACCA	474	154	IGHV2-5_05	IGHJ4_02	0.03	10.72	3.99	Y	Y	99.67	GCACACAGATACT
6	CTGCTGCTGACCA	454	150	IGHV2-5_10	IGHJ5_02	0.03	10.76	11.78	Y	Y	98.99	GCATATGGTGTA
7	CTGCTGCTGACCA	469	139	IGHV2-5_01	IGHJ4_02	0.03	10.78	1.32	Y	Y	97.68	GCACTCGCGACAC
8	CTCGCCCTCCTCC	466	139	IGHV5-51_01	IGHJ4_02	0.03	10.81	7.09	Y	Y	99.32	GCGAGATACTATT
9	CTGCTACTGACTG	490	137	IGHV2-70_10	IGHJ3_02	0.03	10.84	0.66	Y	Y	99.34	GCACGGATTCTC
10	CTGCTGCTGACCA	478	135	IGHV2-5_10	IGHJ6_02	0.03	10.87	3.70	Y	Y	98.99	GCATACACTTGT

Expected Values IGHV SHM

LymphoTrack Report for assay LEADER

Sample name: Leader_positive_S23_L001_001_combined

Total Read Count: 474947

IndexQ30: 87.88

Caution: Do not edit fields and save.

Top 10 Merged Read Summary

Rank	Sequence	Length	Merge count	V-gene	J-gene	% total reads	Cumulative %	Mutation rate to partial V-gene (%)	In-frame (Y/N)	No Stop codon (Y/N)	V-coverage	CDR3 Seq
1	TTCTCGTGGTGCC+	455	50248	IGHV4-59_08	IGHJ4_02	10.58	10.58	11.26	Y	Y	98.63	GCGAGACGGAGC+
2	CTGCTACTGACTG+	319	192	IGHV2-70_10	IGHJ4_02	0.04	10.62	4.32	n/a	N	35.55	not found
3	CTGCTGCTGACCA+	466	175	IGHV2-5_01	IGHJ5_01	0.04	10.66	6.62	Y	Y	100.00	GCACACAGACCGC+
4	CTGCTGCTGACCA+	457	162	IGHV2-5_05	IGHJ6_02	0.03	10.69	2.99	Y	Y	99.67	GCACACAGATACT+
5	CTGCTGCTGACCA+	474	154	IGHV2-5_05	IGHJ4_02	0.03	10.72	3.99	Y	Y	99.67	GCACACAGATACT+
6	CTGCTGCTGACCA+	454	150	IGHV2-5_10	IGHJ5_02	0.03	10.76	11.78	Y	Y	98.99	GCATATGGTGTA+
7	CTGCTGCTGACCA+	469	139	IGHV2-5_01	IGHJ4_02	0.03	10.78	1.32	Y	Y	97.68	GCACTCGCGACAC+
8	CTCGCCCTCCTCC+	466	139	IGHV5-51_01	IGHJ4_02	0.03	10.81	7.09	Y	Y	99.32	GCGAGATACTATT+
9	CTGCTACTGACTG+	490	137	IGHV2-70_10	IGHJ3_02	0.03	10.84	0.66	Y	Y	99.34	GCACGGATTCCCTG+
10	CTGCTGCTGACCA+	478	135	IGHV2-5_10	IGHJ6_02	0.03	10.87	3.70	Y	Y	98.99	GCATACACTTGTT+

- IGH Positive Control top % reads $\geq 2.5\%$
- NGS Negative Control top % reads $< 1.0\%$
- IGH SHM Positive Control (4-088-0008, can be purchased separately) top % reads $\geq 2.5\%$
- IGH SHM Positive Control mutation rate $\geq 2.0\%$
- MiSeq Run Validity Q30 $> 70\%$ for v3 (2x301)

- Will the software work on my computer?
 - The software requires Microsoft Windows 64 bit and Excel
- Do I always need to run the positive & negative controls?
 - Yes, these controls are always recommended & they are the only way our support team can guarantee the assay performed correctly and provide troubleshooting tips to customers
- Two top reasons users have software difficulties:
 - Files named incorrectly. For the MiSeq® our software only recognizes filenames that contain the following characters: A-Z, a-z, 0-9, _ (underscore), - (hyphen)
 - Files from software CD were not copied on the computer or files are zipped
- Reason for low Q30 score on the MiSeq®
 - The Q30 score assesses the flow cell loading. Low scores likely indicate overloading or insufficient DNA quality
 - Q30 ≥ 75% for v2 (2x250); Q30 ≥ 70% for v3 (2x300)

Take Home Message

- Broad menu of standardized kits for both B- and T-cell analysis with included bioinformatics package
- CE-IVD marked kits available
- Higher sensitivity and greater accuracy than traditional methods
- Be part of the community of labs and benefit from great publications and knowhow
- LymphoTrack[®] kits are a great solution for labs that wish to take the next step in their clonality analysis

Full featured solution

- Designed for MiSeq[®], Ion PGM[™] & Ion S5[™]
- One-Step PCR Master Mixes – low contamination risk
- Easy Workflow for the study of Clonality, MRD and SHM analysis
- Flexibility/Scalability
- Multiplexing Targets & Applications
- Included Bioinformatics Software Package
- Comprehensive Technical Support

Name the 4 steps needed to start the analysis in the LymphoTrack[®] software:

1. Log in with username and password

2. Select targets

3. Choose decimal format

4. Browse to BAM files

5. Browse to FASTQ files

6. Select 'Launch Program'

Which of the following are requirements for running the LymphoTrack[®] software:

1. Windows 64 bit
2. Java 8, 64 bit or newer
3. PDF Reader
4. CD-Rom Drive
5. All of the above

LymphoTrack[®] Related Publications





LymphoTrack® Related Publications

Highlights

- Large study with more than 1189 clinical samples
- Great publication for those considering LymphoTrack®
- NGS demonstrates superior performance compared with CE assays
 - higher sensitivity/resolution
 - improved detection
- Good notes with respect to implementation

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

Maria E. Arcila,^{*} Wayne Yu,[†] Mustafa Syed,[†] Hannah Kim,[†] Lidia Maciag,[†] JinJuan Yao,[†] Caleb Ho,[†] Kseniya Petrova,[†] Christine Mounq,[†] Paulo Salazar,[†] Ivelise Rijo,[†] Tessara Baldi,[†] Ahmet Zehir,[†] Ola Landgren,[†] Jae Park,[†] Mikhail Roshal,[†] Ahmet Dogan,[†] and Khedoudja Nafa[†]



LymphoTrack[®] Related Publications


ORIGINAL ARTICLE

Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia

B Stamatopoulos^{1,2,3,7}, A Timbs^{1,7}, D Bruce¹, T Smith⁴, R Clifford^{1,3}, P Robbe^{1,3}, A Burns^{1,3}, DV Vavoulis³, L Lopez⁵, P Antoniou³, J Mason¹, H Dreau¹ and A Schuh^{1,6}

Highlights

- Demonstrates advantage of NGS as compared to Sanger sequencing for determining *IgHV* mutational status and identify the presence of multiple subclones.
- The additional information provided through NGS testing improves disease stratification and prognostication significantly



LymphoTrack® Related Publications

Highlights

- LymphoTrack® detected clonal rearrangements in 94% of Dx cases vs. 89% by CE.
- NGS was equivalent to FC for detection of plasma cell neoplasms (PCN) but showed advantages in disease monitoring for B-ALL, B and T cell lymphomas.

Next Generation Sequencing (NGS) Based IGH and TCR Clonality Assays Provide Excellent Specificity and Sensitivity for Routine Clonal Characterization and Monitoring of Lymphoproliferative Disorders

Maria E. Arcila, Mustafa Syed, Wayne Yu, Hannah Kim, JinYuan Yao, Caleb Ho, Kseniya Petrova-Drus, Mikhail Roshal, Jae H. Park, Ola Landgren, Ahmet Dogan, and Khedoudja Nafa

